Eledon prioritizes kidney transplant program for tegoprubart; Phase 1b data expected Q1 2023

Eledon Pharmaceuticals, Inc.

Ph 1b kidney transplant trial enrollment ongoing; initial 3- and 6-month data at World Congress of Nephrology March 2023.
FDA cleared IND for Phase 2 BESTOW trial (tegoprubart vs tacrolimus, ~120 patients); site initiation mid-2023.
Deprioritizing tegoprubart in IgAN and discontinuing islet cell trial to focus resources on kidney transplantation.
Cash resources sufficient to fund operating activities into 2024 (no specific amount given).
Collaboration with eGenesis for preclinical xenotransplantation studies using tegoprubart.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.